Last reviewed · How we verify
low dose sevoflurane group
At a glance
| Generic name | low dose sevoflurane group |
|---|---|
| Also known as | 1.0 %sevoflurane |
| Sponsor | Yeungnam University College of Medicine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nausea
Key clinical trials
- Emergence Agitation of Sevoflurane in Pediatric (PHASE2, PHASE3)
- The Effect of Esketamine on Postoperative Pain Relief in Patients Undergoing Laparoscopic Surgery (NA)
- Dexmedetomidine Reduces Sevoflurane MAC-BAR During Pneumoperitoneum (PHASE4)
- Enhanced Recovery After Surgery (ERAS) Pathway for Primary Hip and Knee Arthroplasty (NA)
- Efficacy of Low Dose Propofol Given at the End of Sevoflurane Anesthesia for Prevention of Emergence Agitation in Pediatric Patient Undergoing MRI Scan (NA)
- DEX vs SEVO in Congenital Heart Surgery (PHASE4)
- Anesthesia Standard Operating Procedure During On-pump Coronary Artery Bypass Grafting (NA)
- Machine-learning Algorithm to Differentiate Intraoperative Ketamine Dosing Based on Electroencephalographic Density Spectrum Array Analysis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low dose sevoflurane group CI brief — competitive landscape report
- low dose sevoflurane group updates RSS · CI watch RSS
- Yeungnam University College of Medicine portfolio CI